JP2015137277A - トランス−２−ノナデシル−４−ヒドロキシメチル−１、３−ジオキソラン化合物とその調製方法 - Google Patents
トランス−２−ノナデシル−４−ヒドロキシメチル−１、３−ジオキソラン化合物とその調製方法 Download PDFInfo
- Publication number
- JP2015137277A JP2015137277A JP2014085186A JP2014085186A JP2015137277A JP 2015137277 A JP2015137277 A JP 2015137277A JP 2014085186 A JP2014085186 A JP 2014085186A JP 2014085186 A JP2014085186 A JP 2014085186A JP 2015137277 A JP2015137277 A JP 2015137277A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- preparation
- liver
- nonadecyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- -1 Trans-2-nonadecyl-4-hydroxymethyl-1,3-dioxolane compound Chemical class 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 208000019423 liver disease Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000003377 acid catalyst Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000004480 active ingredient Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000269959 Xiphias gladius Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000021335 sword fish Nutrition 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 5
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HPXRASQACBNMFL-DHIUTWEWSA-N [(2R,4R)-2-nonadecyl-1,3-dioxolan-4-yl]methanol Chemical compound C(CCCCCCCCCCCCCCCCCC)[C@@H]1OC[C@H](O1)CO HPXRASQACBNMFL-DHIUTWEWSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/20—Free hydroxyl or mercaptan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW103102539A TWI553000B (zh) | 2014-01-23 | 2014-01-23 | 反式－２－１９烷基－４－羥甲基－１，３－二氧戊環化合物及其製備方法 |
| TW103102539 | 2014-01-23 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095437A Division JP6326086B2 (ja) | 2014-01-23 | 2016-05-11 | トランス−２−ノナデシル−４−ヒドロキシメチル−１、３−ジオキソラン化合物とその調製方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2015137277A true JP2015137277A (ja) | 2015-07-30 |
Family
ID=53544198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014085186A Pending JP2015137277A (ja) | 2014-01-23 | 2014-04-17 | トランス−２−ノナデシル−４−ヒドロキシメチル−１、３−ジオキソラン化合物とその調製方法 |
| JP2016095437A Active JP6326086B2 (ja) | 2014-01-23 | 2016-05-11 | トランス−２−ノナデシル−４−ヒドロキシメチル−１、３−ジオキソラン化合物とその調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095437A Active JP6326086B2 (ja) | 2014-01-23 | 2016-05-11 | トランス−２−ノナデシル−４−ヒドロキシメチル−１、３−ジオキソラン化合物とその調製方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150203466A1 (https=) |
| JP (2) | JP2015137277A (https=) |
| KR (1) | KR101644450B1 (https=) |
| CN (1) | CN104803966A (https=) |
| MY (1) | MY182857A (https=) |
| TW (1) | TWI553000B (https=) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100099894A1 (en) * | 2006-10-09 | 2010-04-22 | Jean-Luc Dubois | Method for the Synthesis of Cyclic Acetals by the Reactive Extraction of a Polyol in a Concentrated Solution |
| WO2011042652A1 (fr) * | 2009-10-06 | 2011-04-14 | Arkema France | Utilisation d'acetals de glycerol comme agents de coalescence pour laques, peintures ou vernis et leurs compositions |
| TW201114465A (en) * | 2009-10-19 | 2011-05-01 | Univ Nat Kaohsiung Marine | Purification process and substance for clam |
-
2014
- 2014-01-23 TW TW103102539A patent/TWI553000B/zh active
- 2014-03-17 CN CN201410099171.4A patent/CN104803966A/zh active Pending
- 2014-03-28 KR KR1020140036865A patent/KR101644450B1/ko active Active
- 2014-04-17 JP JP2014085186A patent/JP2015137277A/ja active Pending
- 2014-08-11 US US14/456,066 patent/US20150203466A1/en not_active Abandoned
- 2014-08-12 MY MYPI2014702242A patent/MY182857A/en unknown
-
2016
- 2016-05-11 JP JP2016095437A patent/JP6326086B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100099894A1 (en) * | 2006-10-09 | 2010-04-22 | Jean-Luc Dubois | Method for the Synthesis of Cyclic Acetals by the Reactive Extraction of a Polyol in a Concentrated Solution |
| WO2011042652A1 (fr) * | 2009-10-06 | 2011-04-14 | Arkema France | Utilisation d'acetals de glycerol comme agents de coalescence pour laques, peintures ou vernis et leurs compositions |
| TW201114465A (en) * | 2009-10-19 | 2011-05-01 | Univ Nat Kaohsiung Marine | Purification process and substance for clam |
Non-Patent Citations (3)
| Title |
|---|
| JPN6015011078; Ｖｅｅｒｅｓａ Ｇｕｄｕｄｕｒｕ， ｅｔ ａｌ．: Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｌｅｔｔｅｒｓ Ｖｏｌ．１６, 2006, ｐｐ．４５１-４５６ * |
| JPN6015011080; Ｖｉｏｌｅｔａ Ｒ． Ｒｕｉｚ， ｅｔ ａｌ．: Ｊｏｕｒｎａｌ ｏｆ Ｃａｔａｌｙｓｉｓ Ｖｏｌ．２７１, 2010, ｐｐ．３５１-３５７ * |
| JPN6015011083; Ｃ． Ｂｒｏｑｕｅｔ， ｅｔ ａｌ．: Ｅｕｒ Ｊ Ｍｅｄ Ｃｈｅｍ Ｖｏｌ．２５, 1990, ｐｐ．２３５-２４０ * |
Also Published As
| Publication number | Publication date |
|---|---|
| MY182857A (en) | 2021-02-05 |
| US20150203466A1 (en) | 2015-07-23 |
| KR101644450B1 (ko) | 2016-08-10 |
| TW201529564A (zh) | 2015-08-01 |
| CN104803966A (zh) | 2015-07-29 |
| TWI553000B (zh) | 2016-10-11 |
| JP6326086B2 (ja) | 2018-05-16 |
| KR20150088162A (ko) | 2015-07-31 |
| JP2016138150A (ja) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9950021B2 (en) | Anti-cancer active substance from Antrodia camphorata, method for preparing the same and use thereof | |
| CN1754541A (zh) | 甾体皂苷药物组合物及其制备方法和用途 | |
| EP3412679B1 (en) | Baicalin magnesium, preparation method thereof and application of same | |
| CN104292278A (zh) | 诃子鞣质类化合物及其制备方法和应用 | |
| US20090318400A1 (en) | Method for inhibiting tumor growth with dehydrosulphurenic acid extracted from antrodia cinnamomea | |
| CN104490894B (zh) | 阔叶丰花草三萜化合物的制备方法及其在制备糖苷酶抑制剂药物中的应用 | |
| CN103012356A (zh) | 一种具有α-糖苷酶抑制活性的化合物及其制备方法和用途 | |
| EP2083806A1 (en) | Use of an anti-cancer compound | |
| CN102093462A (zh) | 1α,2α-二羟基齐墩果酸的制备方法和应用 | |
| WO2017219509A1 (zh) | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮与黄酮醇结合物及其制备方法和应用 | |
| JP6326086B2 (ja) | トランス−２−ノナデシル−４−ヒドロキシメチル−１、３−ジオキソラン化合物とその調製方法 | |
| WO2017219510A1 (zh) | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 | |
| CN113999272A (zh) | 香蜂草苷的制备方法及其应用 | |
| CN102764320B (zh) | 山大颜提取物及其制备方法与抗肿瘤应用 | |
| CN108341849A (zh) | 玉蕊醇类三萜化合物及其制备方法和在制药中的用途 | |
| CN106565641B (zh) | 呋喃半日花烷二萜衍生物及其药物组合物和其在制药中的应用 | |
| CN105837595A (zh) | 阿替洛尔的药物组合物及其在生物医药中的应用 | |
| US11147848B2 (en) | Extracts and isolated compounds from Cakile arabica for treatment of ulcer | |
| US10285972B2 (en) | Trans-2-nonadecyl-4-hydroxymethyl-1,3-dioxolane and producing methodthereof | |
| CN106749124A (zh) | 具有抗肿瘤活性的邻双四氢呋喃型番荔枝内酯类化合物及其制备方法与应用 | |
| US10174072B2 (en) | Antileishmanial compositions and methods of use | |
| CN102633849B (zh) | 环烯醚萜类化合物梓苷的制备方法及抗癌用途 | |
| CN107674065A (zh) | 具有抗肿瘤活性的番荔枝内酯化合物及其应用 | |
| CN102643317A (zh) | 一种制备芝麻素酚三葡萄糖苷的方法 | |
| CN102153529B (zh) | 具有抗肿瘤活性的单四氢呋喃型番荔枝内酯类化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150723 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160112 |